Niagen Bioscience stock rises following positive clinical study

Niagen Bioscience Inc. (NAGE) shares rose 3.5% following the release of a clinical study in Aging Cell demonstrating the safety and efficacy of Niagen® in Werner syndrome (WS) patients. The double-blind, placebo-controlled study showed that daily Niagen supplementation increased blood NAD+ levels by approximately 140% and improved cardiovascular and skin health markers in WS individuals, a rare genetic disorder characterized by rapid aging. The positive results, coupled with the FDA's Orphan Drug Designation and Rare Pediatric Disease Designation for Niagen in treating Ataxia Telangiectasia (AT), suggest potential therapeutic applications in rare progeroid diseases and possibly broader implications for healthy aging.

Analysis

Niagen Bioscience Inc. (NASDAQ:NAGE) observed a 3.5% uplift in its share price following the announcement of compelling results from a clinical study published in *Aging Cell*. This study, the first of its kind, demonstrated both the safety and efficacy of Niagen Bioscience's patented nicotinamide riboside ingredient, Niagen®, in individuals afflicted with Werner syndrome (WS), a rare genetic disorder marked by accelerated aging. The 52-week, double-blind, placebo-controlled crossover trial involving daily 1,000 mg Niagen supplementation resulted in a substantial approximate 140% increase in blood NAD+ levels. Critically, the study also documented significant improvements in several clinical markers of cardiovascular health, such as arterial stiffness and a cardioprotective lipid shift, alongside enhanced skin health, evidenced by reduced skin ulcer size, with no moderate or severe adverse events reported. These outcomes are particularly noteworthy given that Werner syndrome affects between 1 in 380,000 to 1 in 1,000,000 people globally. The U.S. Food and Drug Administration's prior granting of Orphan Drug Designation and Rare Pediatric Disease Designation for Niagen in the treatment of Ataxia Telangiectasia (AT) further reinforces the ingredient's potential in addressing rare, age-related conditions. The positive study findings support further investigation into NAD+ augmentation as a therapeutic strategy for rare progeroid diseases and suggest potential for broader applications in promoting healthier aging within the general population, contributing to the optimistic sentiment reflected in the stock's movement.

Key Decisions for Investors

• The robust clinical trial data demonstrating Niagen's efficacy (c.140% NAD+ increase) and safety in Werner syndrome, coupled with existing FDA designations for Ataxia Telangiectasia, strengthens the company's position in the rare disease and age-related therapeutics market.
• Investors should monitor Niagen Bioscience's subsequent clinical development milestones and regulatory pathway for Niagen®, particularly for Werner syndrome and Ataxia Telangiectasia, as these could serve as significant value inflection points.
• Given the study's positive implications for broader healthy aging and the reported improvements in cardiovascular and skin health markers, consider the long-term potential for Niagen® to address larger markets beyond its current rare disease focus, while acknowledging the initial 3.5% share price increase as a positive market response.